- All
- Anesthesiology
- Anti-infectives and immunology
- Biologicals
- Blood disorders
- Cardiovascular
- CNS
- Diabetes
- Endocrinology/Sexual health
- Gastrointestinal Diseases
- General modelling
- Lung Diseases
- Methods
- Oncology
- Paediatrics
- Pain
- Peripheral Nervous System
- Safety pharmacology
Trame M.N., Post T.M. Session 1c: A Perspective on integrating Pharmacometrics and Quantitative Systems Pharmacology characteristics using examples. ACoP9, 2018. [Link to publication]
Post T.M. Application of an iPSP Model with Reduced Mechanistic Detail for a Disease System Analysis applied to Osteoporosis. ACoP9, 2018. [Link to publication]
Fidler M., Wang W., Post T.M., Wilkins J., Schoemaker R., Trame M.N. Tutorial 1: nlmixr: Population Modeling in R. ACoP9, 2018. [Link to publication]
Fidler M, Xiong Y, Schoemaker R, Wilkins J, Trame M.N, Post T.M, Hooijmaijers R, Wang W., Solving sensitivity equations by inductive linearization and its applications in population pharmacokinetic and pharmacodynamic models via FOCEi. ACoP9 2018
Fidler M, Xiong Y, Schoemaker R, Wilkins J, Trame M.N, Post T.M, Hooijmaijers R, Wang W. Exploring inductive linearization in population pharmacokinetic and pharmacodynamic models. ACoP9, 2018.
Ploeger B., Cleton A., Keunecke A., Bruix J., Meinhardt G. Population pharmacokinetics (popPK) to evaluate the effect of intrinsic and extrinsic factors on regorafenib (REG) exposure in REG studies including patients with hepatocellular carcinoma (HCC). The American Society of Clinical Oncology – Gastrointestinal Cancers Symposium, 2017.
Maanen E.M.T.v., Steeg T.J.v., Kalinina J., Michener M.S., Savage M.J., Kennedy M.E., Parker E.M., Danhof M. Systems pharmacology analysis of the Aβ oligomer response following β-secretase inhibition: Evidence for second-order kinetics of Aβ42 oligomerization. AAIC, 2017.
Maanen E.M.T.v., Steeg T.J.v., Kalinina J., Michener M.S., Savage, M.J., Kennedy M.E., Parker E.M., Danhof, M. A systems pharmacology approach unfolds Aβ oligomer modulation and unravels the dynamics of the APP pathway. Page 2017. [Link to publication]
Maanen E.M.T., Steeg, TJ.v., Kalinina J., Stone, J., Michener M.S., Savage M.J., Parker E.M., Danhof, M. Resilience in the Amyloid Precursor Protein ( APP ) pathway revealed by systems pharmacology modeling following β – and γ -secretase inhibition. AAIC, 2017.
Schulthess P., Post T.M., Yates J., Graaf H.J.v.d. Frequency-domain response analysis for quantitative systems pharmacology models. PAGE, 2017. [Link to publication]
Vis P., Snelder N., Ahsman M., MacLean D. and Faessel H., Optimization of trial design and dose selection based on the quantitative assessement of the efficacy of TAK-385. WCOP, (2016).
Snelder N. and Steeg T.v., QSP Modelling at the heart of the action. ACoP, (2016).
Maanen E.v., Steeg T.v., Savage M.J., Michener M.S., Stone J. and Danhof M., Quantification of the modulation of the Aβ oligomers following secretase inhibition; A systems pharmacology approach. Computational Hub Meeting.(2016)
Maanen E.v., Steeg T.v., Kalinina J., Stone J., Michener M.S., Savage M.J., Parker E.M. and Danhof M. (2016). Quantification of the modulation of Aβ oligomers following secretase inhibition- A systems pharmacology approach. ACOP (2016)
Snelder N., Drenth H., Bergmann K., Wood N., Hibberd M. and Scott G., PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin. What is the optimal testosterone level?, PAGE.(2015) [Link to publication]